Pyxis Oncology FY2030 EPS Forecast Reduced by HC WainwrightMarket Beat·2 days ago, 07:57 AMPYXS-0.48%
Buy Rating Reiterated on MICVO’s Differentiated Profile and 2026 Data Catalysts; $6 Price Target MaintainedTip Ranks·Aug 14 at 12:05 PMPYXS-0.48%
Popular pre-market trades in the US stock market: Pyxis Oncology up 9.97% in pre-market; Aehr Test up 8.27% in pre-marketPrice Alert·Aug 14 at 06:09 AMPYXS-0.48%AEHR-4.60%
Pyxis Oncology Faces Mounting Dilution Risk as Ongoing Equity Raises and Warrants Pressure Shareholder ValueTip Ranks·Aug 14 at 01:01 AMPYXS-0.48%
Pyxis Oncology (NASDAQ:PYXS) Releases Quarterly Earnings Results, Misses Expectations By $0.06 EPSMarket Beat·Aug 13 at 08:11 PMPYXS-0.48%
Pyxis Oncology posts corporate deck spotlighting MICVO extracellular-targeting ADC in head-and-neck cancerPUBT·Aug 13 at 06:17 AMPYXS-0.48%
U.S. stock market midday update: Pyxis Oncology up 12.37%, soaring 135% in six months, is there a surge driven by funds without good news?Price Alert·Aug 12 at 01:13 PMPYXS-0.48%
12 Health Care Stocks Moving In Tuesday's Intraday Sessionbenzinga_article·Aug 11 at 12:06 PMALMR-0.45%GRI-1.20%
This Charles Schwab Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Mondaybenzinga_article·Aug 3 at 09:24 AMYARW-4.95%SCHW+1.96%
Pyxis Oncology files Form 3 beneficial ownership statement for GordonMD Global Investments LPPUBT·Jul 10 at 03:11 PMPYXS-0.48%
Biotech and CXO Clinical Momentum: 7 Core Companies Set for Late-2026 BreakoutsGlobal Report·Jul 9 at 05:02 AMBVS-0.42%ALT+6.27%
